Pyrimidine Compounds Inhibiting Dengue Virus Entry via Abl Kinase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for dengue and West Nile viruses are lacking, with no prophylactic vaccines or effective treatments available, and there is a need for therapies that do not harm host cell viability.
Innovation Solution
Development of specific compounds, such as GNF-2 and its derivatives, which inhibit dengue virus entry by targeting Abl kinases and the viral envelope protein, potentially using dual-action mechanisms to block viral replication and fusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used, then viral replication may be inhibited, but host cell viability is harmed
Solution Approach 1:
The patent uses host cell Abl kinases as intermediary targets. Instead of directly targeting viral components which may cause broad-spectrum toxicity, the compounds indirectly inhibit viral replication by modulating host cell signaling pathways through Abl kinase inhibition. This intermediary approach allows selective antiviral activity while sparing direct viral structures that would require more aggressive inhibition.
Solution Approach 2:
The invention exploits the virus's own entry mechanism as its vulnerability. By inhibiting Abl kinases that are essential for viral entry and replication, the therapy makes the virus dependent on host cell pathways that can be selectively modulated. The virus essentially serves its own defeat by relying on the very host pathways that the drug targets.
2Reliability
If single-target antiviral mechanisms are used, then specific viral functions can be inhibited, but viral resistance develops
Solution Approach 1:
The patent employs compounds that exhibit multi-functionality by simultaneously targeting multiple aspects of the viral life cycle through Abl kinase inhibition. The single compound performs multiple functions: inhibiting viral entry, blocking replication, and preventing assembly/release. This multi-functional approach creates multiple barriers to resistance development, as the virus would need to overcome multiple simultaneous inhibitions.
Solution Approach 2:
The invention merges multiple antiviral activities into a single therapeutic agent. By combining entry inhibition, replication blocking, and assembly prevention through the common mechanism of Abl kinase inhibition, the patent creates a unified therapeutic approach that addresses multiple vulnerabilities in the viral life cycle simultaneously, reducing the likelihood of resistance emergence.
3Loss of time
If early viral entry is not blocked, then viral replication proceeds, but therapeutic intervention opportunities are lost
Solution Approach 1:
The patent implements preliminary action by blocking viral entry at the earliest stage of infection through Abl kinase inhibition. By preventing the virus from entering host cells in the first place, the therapy stops the infectious cycle before replication can begin. This preliminary blockade creates an extended therapeutic window by preventing viral establishment rather than attempting to intervene during active replication.
Data Source
AI summary
Disclosed herein are pyrimidine compounds of formula I and formula II and methods for treating or preventing a viral infection, such as infections caused by dengue virus in a subject, comprising administering to said subject an effective amount of a pyrimidine compound of formula I or formula II.